Procore stock price target raised to $90 from Goldman Sachs on stabilizing growth
Investing.com - RBC Capital lowered its price target on Inspire Medical Systems (NYSE:INSP) to $125 from $150 while maintaining an Outperform rating. The new target still suggests significant upside from the current price of $73.71, with INSP trading near its 52-week low of $70.77 and approximately 66% below its 52-week high of $216.01.
The firm cited Inspire Medical’s "early indication" of 10-11% year-over-year growth for 2026, which falls below the consensus expectation of 14% growth, despite positive early metrics from the Inspire V device ramp-up. This projection comes as InvestingPro data shows the company achieved 16.8% revenue growth over the last twelve months, suggesting a potential slowdown ahead. According to InvestingPro’s Fair Value analysis, INSP appears undervalued despite its recent challenges.
Inspire Medical reported third-quarter revenue growth of 10.5% year-over-year, consistent with the second quarter but below the first quarter’s 22.7% growth, reflecting what RBC described as "a year still in transition."
The company delivered a marginal third-quarter revenue beat of 2% but significantly exceeded earnings per share expectations by $0.57 on what RBC characterized as "a low bar."
RBC suggested that Inspire’s 2026 guidance represents a "base case off which it can make room to beat/raise" and provides flexibility for potential headwinds and tailwinds as the business develops.
In other recent news, Inspire Medical Systems reported third-quarter 2025 revenue of $224.5 million, surpassing analyst expectations of $220.4 million. The company’s earnings per share were $0.38, significantly exceeding the forecasted loss of $0.20 per share. Piper Sandler adjusted its price target for Inspire Medical Systems to $135, maintaining an Overweight rating, citing a slower growth outlook. Mizuho also lowered its price target to $110 but kept an Outperform rating, noting a $4 million revenue beat primarily driven by international markets. KeyBanc maintained its Sector Weight rating, acknowledging signs of incremental stability in the company’s results. Wells Fargo upgraded the stock from Equal Weight to Overweight, despite reducing the price target to $90, highlighting a positive risk/reward profile. These developments reflect a mix of optimism and caution among analysts regarding Inspire Medical Systems’ future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.